Today’s rally breaks the stock into new-high territory in a clear move by investors to start buying HIM stock ahead of its next quarterly report on March 3. The move is also being fueled by a positive ...

YouTube's latest "AdBlitz" hub allows advertisers to showcase and tease their biggest ads of the year to curious viewers via categorized in-app playlists.

In a remarkable display of market confidence, HIMS & Hers Health, Inc. (HIMS) stock has soared to an all-time high, reaching ...

Bank of America Securities analyst Allen Lutz maintained a Buy rating on Cardinal Health (CAH – Research Report) today. The company’s shares ...

In a report released yesterday, Allen Lutz from Bank of America Securities reiterated a Hold rating on Doximity (DOCS – Research Report), with ...

Telehealth company's spot decries medications from others as "priced for profits, not patients," while its own weight-loss ...

Why have drugs to treat the liver disease MASH reached a tipping point? How did Hims & Hers convince Childish Gambino to ...

Hims & Hers releases Super Bowl ad criticizing pharmaceutical industry and weight loss market, promoting their compounded GLP ...

Hims evaluates the nutrition of easy-prep slow cooker recipes designed to get your tailgate party off to a fun and healthy ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the ...

Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $31.86 which represents a slight increase of $0.32 or 1.01% from the prior close of $31.54. The stock opened at $31.9 and ...

AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...